No Data
Livzon Pharmaceutical Group Inc. (SZSE:000513) Looks Inexpensive But Perhaps Not Attractive Enough
AI and policy are driving forces! Hong Kong pharmaceutical stocks collectively "rebound" with WUXI BIO surging over 14% to lead the Industry.
① What technological breakthroughs have driven the improvement of research and development efficiency in the Biomedical Industry? ② What are the reasons for the leading increase in WuXi's affiliated companies?
Hong Kong stocks are experiencing fluctuations | CRO Concept stocks are warming up. The integration of AI and CXO has entered a new stage. Institutions claim that the external environment for CRO may be improving.
As of the time of writing, the CRO Concept has warmed up, with VIVA BIOTECH (01873) rising by 11.89% to 1.6 HKD; WUXI BIO (02269) increasing by 10.3% to 25.7 HKD; PHARMARON (03759) up by 5.67% to 16.04 HKD; and TIGERMED (03347) climbing by 5.86% to 37.05 HKD.
LIVZON PHARMA (01513.HK) plans to hold a Board of Directors meeting on March 26 to approve the annual performance.
Gelonghui reported on March 12 that LIVZON PHARMA (01513.HK) announced that the Board of Directors has scheduled a board meeting on Wednesday, March 26, 2025, to review and approve the annual results of the company and its subsidiaries for the year ending on March 12, 2025, consider the proposal for the final dividend distribution (if applicable), and address other matters (if any).
LIVZON PHARMA: Date of Board Meeting
National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two
① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Yet
